Clinical Report: A Reversible Autonomic-Endothelial Migraine Phenomenon

Overview

This case study presents a 41-year-old male with a 10-year history of migraine who achieved sustained remission following antihypertensive therapy. The findings suggest a potential link between endothelial and autonomic modulation in migraine management.

Background

Migraine is a prevalent neurovascular disorder that can significantly impact quality of life. Recent research indicates that systemic endothelial and autonomic factors may play a crucial role in the modulation of migraine attacks. Understanding these factors could lead to improved treatment strategies and better patient outcomes.

Data Highlights

No numerical data or trial data was provided in the article.

Key Findings

• The patient experienced migraine without aura, fulfilling ICHD-3 criteria.
• Attacks were triggered by strong odors and accompanied by cranial-autonomic symptoms.
• Combined antihypertensive therapy led to normalization of blood pressure and resolution of migraine symptoms.
• Remission persisted for 12 months post-therapy initiation.
• The case suggests a potential role of endothelial and autonomic modulation in migraine management.

Clinical Implications

This case highlights the importance of considering systemic factors, such as endothelial and autonomic balance, in the management of migraine. Clinicians may explore antihypertensive therapies as a potential treatment avenue for patients with similar presentations.

Conclusion

The observed sustained remission in this case underscores the need for further investigation into the role of vascular and autonomic factors in migraine pathophysiology and treatment.

Related Resources & Content

1. Jannetta, P., Springer, 2024 -- Vascular Compression of the Lateral Medulla Resulting in Episodes of Hypertension
2. Brain, 2024 -- Activation and Sensitization of Meningeal Pain Receptors by PACAP-38: Consequences for Migraine Headaches
3. Brain, 2024 -- Connecting the Dots: Molecular Mechanisms, Regional Activity, and Neural Connectivity in Headache Disorders
4. Brain, 2024 -- Trigeminal nerve microstructure is linked with neuroinflammation and brainstem activity in migraine
5. Neuroamerica, 2024 -- CGRP-targeting therapies are a first-line option for the prevention of migraine
6. PubMed, 2024 -- Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial
7. The Journal of Headache and Pain, 2024 -- Vascular responses to molecular migraine triggers: a systematic review of magnetic resonance angiography studies
8. Received: 6 February 2024 | Accepted: 22 February 2024
9. Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial - PubMed
10. Vascular responses to molecular migraine triggers: a systematic review of magnetic resonance angiography studies | The Journal of Headache and Pain | Springer Nature Link